The anticancer immune response: indispensable for therapeutic success?
about
Towards tumor immunodiagnosticsMesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune TargetingThe effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune responseImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyCombining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyImmunotherapy for prostate cancer: recent developments and future challengesImmunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancerEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesImmune microenvironment in colorectal cancer: a new hallmark to change old paradigmsRole of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implicationsWhat future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?Trends and advances in tumor immunology and lung cancer immunotherapyImmunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor MicroenvironmentNKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple MyelomaProspects of immune checkpoint modulators in the treatment of glioblastomaCompartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune functionEnhanced antitumor immunity contributes to the radio-sensitization of ehrlich ascites tumor by the glycolytic inhibitor 2-deoxy-D-glucose in miceEpirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell ActivityCD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humansHPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.An agent-based modeling framework linking inflammation and cancer using evolutionary principles: description of a generative hierarchy for the hallmarks of cancer and developing a bridge between mechanism and epidemiological dataPersonalized therapy for metastatic melanoma: could timing be everything?Autophagy and cancer therapy.Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine.Calreticulin: non-endoplasmic reticulum functions in physiology and disease.Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress.Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines.Toll-like receptor agonists in cancer therapy.Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker.Pattern response of dendritic cells in the tumor microenvironment and breast cancerNiche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering.Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responsesLigand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunityMacrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progressionChemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanismsCD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation
P2860
Q26738691-586A6A24-398D-4AC1-B9EB-1C913BD350B9Q26746104-265CD8D9-AE87-45EC-89A9-2D258DD7CB86Q26747695-2382BD1B-EEC4-4EAE-BF3F-01F39C671045Q26747792-4172A241-A078-4E3D-B2AC-72B582CD0366Q26766066-8AC175AC-4492-48F2-A15D-8F5E8ACB4197Q26781538-C7655D42-5D79-4705-97B5-C762A8CFCA9BQ26825053-9D7F3C1B-5D86-436A-A6AD-5083AEE4D630Q26851608-9E43B5E1-BC32-415D-9CBC-49A3F024B788Q26852388-FDF71776-390B-48A2-ABFB-F77400B4B176Q26996829-5F0F2B7D-9249-4B28-910D-28116FA5F565Q27008070-FB370D4B-BAE1-416A-80A1-CCACABFE6BBFQ27008654-C9C53701-5501-4815-A69D-0775EE9F77D2Q27011510-3159B3F8-4BA4-4828-8EC1-F4EF76C08CE6Q27012886-F74D894B-0F2C-4B53-9561-0A61BB2D5F09Q28067674-FEC792F5-D3BB-4C6D-BE25-55F1A6F5959FQ28071935-9992558E-98E6-4545-9FCA-A6106EF60327Q28080823-00B78A36-1C27-4E0E-947B-0E1AE7087F01Q28081371-02953598-206E-41E9-9338-76C3C56CD0E1Q28383385-7BF1C4F2-D708-4C18-AB7E-BCB5EF6BD863Q28543176-F02EFEF1-4E5C-490F-89BC-603B433C2DB3Q28550203-A5490998-4AEC-458F-817E-4C8AECB149EEQ29614348-644AEAFC-951A-40C8-A643-D2B3F27F0678Q30538743-062C96D1-8789-4CF4-9F63-F809D6F91151Q30840391-2AD79167-A6E7-4F71-8DAD-B9BC7216CC6DQ33576035-457D8419-811F-4AD2-9DB6-5E3D37165EE1Q33584607-0915CF88-6D84-41B0-97F7-69A9B1972516Q33622752-C3AAF4DD-4754-42D9-BF96-C289C707D891Q33694634-E9A4F63D-7E2F-420C-A188-E5735C14B83FQ33776397-C501AE49-2278-4B6C-ADF7-552D7594A966Q33908539-E7556E8C-82F1-4FE6-AAF6-5104EC440A07Q33918509-A7C97BFB-D683-419B-AE89-A4A113E372B6Q34009845-FCA35EE4-7C9B-4CE2-90D4-00546571B1F1Q34023724-77805915-7E12-4FC9-B3CD-AFA58E37A61EQ34086276-8E996261-61E2-45F6-98B2-01B72DB6BEA7Q34097414-479D0667-5ACE-4D2A-A04D-9D7AD5E98614Q34135426-2AF7A507-1F34-4C13-B50D-FD46E2A6CD6CQ34153811-95E59484-DE6D-47A4-BC7B-A57A65EE07DFQ34168497-0349A9F2-F34F-4531-A410-5C3C83A3D329Q34343736-E1AC0BAD-DB98-4D4D-A7E5-457FEFD2D9B6Q34346803-DF8881CD-6148-45A7-A48C-897B465B3DCC
P2860
The anticancer immune response: indispensable for therapeutic success?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The anticancer immune response: indispensable for therapeutic success?
@ast
The anticancer immune response: indispensable for therapeutic success?
@en
type
label
The anticancer immune response: indispensable for therapeutic success?
@ast
The anticancer immune response: indispensable for therapeutic success?
@en
prefLabel
The anticancer immune response: indispensable for therapeutic success?
@ast
The anticancer immune response: indispensable for therapeutic success?
@en
P2860
P50
P356
P1476
The anticancer immune response: indispensable for therapeutic success?
@en
P2860
P304
P356
10.1172/JCI35180
P407
P577
2008-06-01T00:00:00Z